Emergent BioSolutions (EBS) Assets (2010 - 2026)

Emergent BioSolutions' Assets history runs 17 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• On a quarterly basis, Assets fell 7.41% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 7.41% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, down 5.12% from the prior year.
• Assets held at $1.3 billion in Q1 2026 per EBS's latest filing, from $1.3 billion in the prior quarter.
• Across five years, Assets topped out at $3.2 billion in Q4 2022 and bottomed at $1.3 billion in Q4 2025.
• The 5-year median for Assets is $1.8 billion (2024), against an average of $2.0 billion.
• Across the five-year window, Assets grew 7.05% in 2022 and slumped 42.42% in 2023, its largest moves.
• Year by year, Assets stood at $3.2 billion in 2022, then slumped by 42.42% to $1.8 billion in 2023, then fell by 23.78% to $1.4 billion in 2024, then declined by 5.12% to $1.3 billion in 2025, then advanced by 0.14% to $1.3 billion in 2026.
• Per Business Quant, the three latest EBS Assets figures stand at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.5 billion (Q3 2025).